- Strong revenue growth (+42%) with significantly improved EBITDA (record level of EUR 38.3 M vs. EUR -18.4 M in 2017) and cash position (EUR 119 M vs. EUR 36.2 M in 2017) thanks to increased business development activities
- Strengthening Mithra’s international deployment through key partnerships with women’s health leaders
- Clinical milestones successfully achieved for highly promising portfolio E4 (Estetrol)-based pipeline, including the 5th generation contraceptive pill Estelle® and next-generation menopause therapy Donesta®
- Additional potential E4-based blockbuster for the underserved perimenopause market with PeriNesta™ in development (which brings Mithra’s late clinical stage pipeline to a total of 3)
Liege, Belgium, 01 March 2019– 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its results for the year ended 31 December 2018, prepared in accordance with IFRS.